A Study in Healthy People to Compare Two Tablet Formulations of Pramipexole

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

NCT01214109 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease

NCT02231905 ·Status: COMPLETED ·Phase: PHASE4

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

NCT00472199 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

NCT00275457 ·Status: COMPLETED ·Phase: PHASE3

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

NCT00152997 ·Status: COMPLETED ·Phase: PHASE2

Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life

NCT01100073 ·Status: COMPLETED

Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

NCT02248207 ·Status: COMPLETED

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

NCT02261090 ·Status: COMPLETED ·Phase: PHASE1

Pramipexole Conversion to Ropinirole Controlled Release (CR)

NCT00275275 ·Status: COMPLETED ·Phase: PHASE3

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

NCT00654498 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

NCT02248220 ·Status: COMPLETED

The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

NCT02236741 ·Status: COMPLETED

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

NCT02261103 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198 ·Status: COMPLETED ·Phase: PHASE3

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

NCT02264132 ·Status: COMPLETED ·Phase: PHASE1

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

NCT02236728 ·Status: COMPLETED

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

NCT01097421 ·Status: COMPLETED

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300 ·Status: COMPLETED ·Phase: PHASE4

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

NCT02233023 ·Status: COMPLETED ·Phase: PHASE4

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

NCT02248142 ·Status: COMPLETED

Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

NCT02248181 ·Status: COMPLETED

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

NCT00297778 ·Status: COMPLETED ·Phase: PHASE4

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

NCT02177357 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

NCT00274131 ·Status: COMPLETED ·Phase: PHASE3